caa a22 4500 477058132 CHVBK 20180405111352.0 cr unu---uuuuu 170330e19960201xx s 000 0 eng 10.1007/BF00203775 doi (NATIONALLICENCE)springer-10.1007/BF00203775 Controlled trial of methotrexate in patients with severe chronic asthma [Elektronische Daten] [J. Hedman, B. Steinus-Aarniala, P. Seideman, F. Albertioni] The aim of this study was to investigate the efficacy and adverse effects of methotrexate (MTX) in the treatment of severe chronic asthma in 12 patients with severe asthma requiring continuous treatment with oral steroids at the Outpatient Department of Helsinki University Central Hospital. The study was a randomised, double-blind placebo-controlled trial of methotrexate treatment 15 mg weekly on a crossover basis over 24 weeks. During the 2 weeks baseline phase the mean dose of oral steroids administered was 10.9 (3.2-28) mg · day−1, and the mean dose of inhaled steroids administered was 2.3 (1.6-3.2) mg budesonide or beclomethasone. The average dose of oral steroids administered was 12.8 mg · day−1 during the last 2 placebo weeks but only 7.9 mg · day−1 during the last 2 weeks with MTX treatment. The reduction in daily dose of oral steroids was 38%, while daily bronchodilator use was reduced by 22%. During MTX treatment the patients experienced significantly less wheezing, dyspnoea and coughing. Nine out of 12 patients reported better asthma control during MTX treatment. The peak expiratory flow rate (PEF) 1-s forced expiratory volume (FEV1) values did not differ between MTX and placebo treatments. There was no statistical correlation between serum MTX concentration and clinical improvement. No serious adverse effects of MTX were found during the study. It was concluded that low-dose MTX may be beneficial for severe chronic asthma and that this therapy is well tolerated by patients. Springer-Verlag, 1996 Asthma nationallicence Methotexate nationallicence steroid-sparing effect nationallicence blood levels nationallicence Hedman J. Department of Pulmonary Medicine, Helsinki University Central Hospital, Haartmanninkatu 4, SF-00290, Helsinki, Finland aut Steinus-Aarniala B. Department of Pulmonary Medicine, Helsinki University Central Hospital, Haartmanninkatu 4, SF-00290, Helsinki, Finland aut Seideman P. Rheuma Center, St. Göran Hospital, S-11281, Stockholm, Sweden aut Albertioni F. Department of Clinical Pharmacology, Karolinska Hospital, S-10401, Stockholm, Sweden aut European Journal of Clinical Pharmacology Springer-Verlag 49/5(1996-02-01), 347-349 0031-6970 49:5<347 1996 49 228 https://doi.org/10.1007/BF00203775 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00203775 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Hedman J. Department of Pulmonary Medicine, Helsinki University Central Hospital, Haartmanninkatu 4, SF-00290, Helsinki, Finland aut NATIONALLICENCE 700 1- Steinus-Aarniala B. Department of Pulmonary Medicine, Helsinki University Central Hospital, Haartmanninkatu 4, SF-00290, Helsinki, Finland aut NATIONALLICENCE 700 1- Seideman P. Rheuma Center, St. Göran Hospital, S-11281, Stockholm, Sweden aut NATIONALLICENCE 700 1- Albertioni F. Department of Clinical Pharmacology, Karolinska Hospital, S-10401, Stockholm, Sweden aut NATIONALLICENCE 773 0- European Journal of Clinical Pharmacology Springer-Verlag 49/5(1996-02-01), 347-349 0031-6970 49:5<347 1996 49 228 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer